Dieses Kaninchen Polyklonal-Antikörper erkennt spezifisch BRCA2 in IHC (fro). Er zeigt eine Reaktivität gegenüber Human, Ratte, Maus, Affe, Cat, Hund und Pferd.
This antibody is specific for Breast Cancer Type 2 susceptibility protein (BRCA2), a tumour-suppressor protein reported to be involved in double-strand break repair, homologous recombination and S-phase checkpoint activation. Based on sequence similarity, is expected to react with: Mouse, Rat, Horse, Cat, Chimpanzee, Rhesus Monkey and Dog.
Aufreinigung
Purified IgG prepared by affinity chromatography on Protein G
Immunogen
Synthetic peptide corresponding to amino acids 2587-2601 of the human BRCA2 precursor, conjugated to Keyhole Limpet Haemocyanin.
BRCA2
Reaktivität: Human
WB
Wirt: Maus
Monoclonal
1643CT739-91-87
unconjugated
Applikationshinweise
Immunohistochemistry on Frozen Sections. Immunohistochemistry on Paraffin Sections (1/25-1/100): This product requires antigenretrieval using heat treatment prior to staining of paraffin sections. Other applications not tested. Optimal dilutions are dependent on conditions and should be determined by the user.
Beschränkungen
Nur für Forschungszwecke einsetzbar
Format
Liquid
Konzentration
5.0 mg/mL
Buffer
Phosphate buffered saline containing 0.09 % Sodium Azide as preservative.
Konservierungsmittel
Sodium azide
Vorsichtsmaßnahmen
This product contains sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
Handhabung
Avoid repeated freezing and thawing. Should this product contain a precipitate we recommend microcentrifugation before use.
Lagerung
4 °C/-20 °C
Informationen zur Lagerung
Store the antibody undiluted at 2-8 °C for one month or (in aliquots) at -20 °C for longer.
Target
BRCA2
(Breast Cancer 2, Early Onset (BRCA2))
Andere Bezeichnung
BRCA2 / FANCD1
Hintergrund
BRCA 2 is localized to chromosome 13q12 - q13. Loss of heterozygosity of 13q is observed in 25 % of sporadic breast tumors, which indicates that BRCA 2 might be a tumor suppressor gene. BRCA 2 confers only a low ovarian cancer risk. Reportedly, in MCF-10F (normal breast epithelial cell line) and MCF-7 (breast cancer cell line) cells the expression of BRCA 2 RNA lowers in G0 and early G1 phases then gets up-regulated at the G1 / S phase junction.Synonyms: Breast cancer type 2 susceptibility protein, FACD, Fanconi anemia group D1 protein